Target Price | €175.95 |
Price | €105.60 |
Potential |
66.62%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Redcare Pharmacy 2026 .
The average Redcare Pharmacy target price is €175.95.
This is
66.62%
register free of charge
€224.70
112.78%
register free of charge
€94.94
10.09%
register free of charge
|
|
A rating was issued by 17 analysts: 12 Analysts recommend Redcare Pharmacy to buy, 3 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Redcare Pharmacy stock has an average upside potential 2026 of
66.62%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion € | 2.37 | 3.01 |
31.79% | 27.06% | |
EBITDA Margin | 1.26% | 2.16% |
54.51% | 71.94% | |
Net Margin | -1.92% | -0.74% |
186.50% | 61.41% |
14 Analysts have issued a sales forecast Redcare Pharmacy 2025 . The average Redcare Pharmacy sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Redcare Pharmacy EBITDA forecast 2025. The average Redcare Pharmacy EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Redcare Pharmacy Analysts have issued a net profit forecast 2025. The average Redcare Pharmacy net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share € | -2.27 | -1.10 |
260.32% | 51.54% | |
P/E | negative | |
EV/Sales | 0.74 |
14 Analysts have issued a Redcare Pharmacy forecast for earnings per share. The average Redcare Pharmacy EPS is
This results in the following potential growth metrics and future valuations:
Redcare Pharmacy...
Analyst | Rating | Action | Date |
---|---|---|---|
BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Apr 06 2025 |
WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
METZLER EQUITIES |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
BERENBERG |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
HSBC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
Analyst Rating | Date |
---|---|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Apr 06 2025 |
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Apr 03 2025 |
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Apr 03 2025 |
Locked
METZLER EQUITIES:
Locked
➜
Locked
|
Apr 03 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
Apr 02 2025 |
Locked
BERENBERG:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
HSBC:
Locked
➜
Locked
|
Mar 23 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.